Tempus AI stock has been attracting a lot of attention lately, and we can see why. The stock offers exposure to AI in a way that's set to transform the healthcare industry. Tempus sells genetic tests, captures data from those tests, then licenses that data to pharmaceutical companies, collecting fees on it for years to come. The business model is a lucrative one, attracted attention from ARK Invest's Cathie Wood herself. We don't invest based on hype, so today we'll analyze TEM stock to see if it's a buy now.

Stay informed with our free disruptive technology investing newsletter, Nanalyze Weekly. Sign up now at https://www.nanalyze.com/nanalyze-weekly/. This episode is pulled from a YouTube presentation. View the original presentation at https://youtu.be/qKXqJGswsIQ.